TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06381726

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Resting State Functional Magnetic Resonance Imaging (rs-fMRI)
Description: rs-fMRI + neurological and neuropsychological evaluation at preoperative timepoint and 1-2 months postop, 3-4 months postop, 6-8 months postop, 12 months postop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up-front Motor Rehabilitation
Description: personalized motor rehabilitation for 6 months + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months postop

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up-front Motor Rehabilitation
Description: personalized motor rehabilitation for 6 months + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months postop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up-front Chemotherapy
Description: Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Up-front Chemotherapy
Description: Temozolomide at either 6 cycles consisting of 150-200 mg per square meter for 5 days during each 28-day cycle, or metronomic schedule, + rs-fMRI + neurological and neuropsychological evaluation before starting motor rehabilitation, at 2-3 months during rehabilitation, 6-9 months during rehabilitation, before surgery (if surgery indicated by tumour board), 1 month postop, 2-3 months Post
Study: NCT06450600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Therapeutic Education Program
Description: The MS Self-Management Education Workshop is designed as an integral part of our therapeutic education program targeting individuals diagnosed with multiple sclerosis (MS). This intervention focuses on empowering participants with knowledge and skills necessary for effective self-management of their condition. The workshop includes interactive sessions that cover a range of topics critical for MS patients, such as:~Understanding the nature and progression of MS, highlighting the importance of early symptom recognition and management strategies.~Techniques for managing common MS symptoms, including fatigue, mobility issues, and cognitive challenges, with practical advice on daily living adaptations.~Guidance on medication management, including the use of disease-modifying therapies and managing side effects.~Strategies for emotional well-being, including coping mechanisms for dealing with the psychological impact of MS, stress management, and fostering resilience.
Study: NCT06670742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: running
Description: Running 10 kilometers on a treadmill
Study: NCT06670833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Portable lung ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: SOC antibiotic treatment
Study: NCT06367504

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DBMF
Description: Once a day daily 30 minutes before lunch

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day daily 30 minutes before lunch
Study: NCT04601883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: The intervention tablets are commercially available Colchicine Tiofarma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated placebo tablets. Placebo is identical to the active intervention.
Study: NCT06240403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin 0.125 MG
Description: One capsule containing digoxin per day for three months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Digoxin 0.125 MG
Description: One capsule containing digoxin per day for three months
Study: NCT05867615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-PSMA I&T
Description: 177Lu activity to be administered to single patient (range 5.5-7.4 GBq), every 8 weeks (±2 weeks) will be measured in a dose calibrator, properly calibrated for the radionuclide. The radiopharmaceutical will be slowly infused intravenously over 15-30' in a dedicated room using a dedicated pump system.
Study: NCT06291298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGMUSE-AUT
Description: The computerized training exercises and brain games help stimulate cognitive functions while providing real-time monitoring on the evolution of participants' skills.
Study: NCT06266611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fsCBD Cannabidiol
Description: Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsCBD Cannabidiol
Description: Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
Study: NCT06168994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Amiodarone vs eplerenone in AF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: Amiodarone vs eplerenone in AF
Study: NCT06291935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG901
Description: Administered as specified in the treatment arm. Study Cohort 1 - Low dose; Study Cohort 2 - High dose~Other Names:~Gene Therapy (AAV2.NN-CNGA1)
Study: NCT06025526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aktivplan
Description: The aktivplan digital intervention consists of a digital planning calendar for regular heart-healthy physical activity Towards the end of rehabilitation phase II, health professionals introduce aktivplan and plan a personalised physical activity plan together with their patients using shared decision-making. The physical activity plan is devised for the time after discharge from cardiac rehabilitation.~In the aktivplan smatphone app, the patient can view their personalised physical activity plan, check off completed activities, enter additional unplanned activities, and open short videos with exercise instructions.~Additional functions of aktivplan include patient-centered goal-setting, automated messages to the patient (motivational messages and reminders), and the possibility for health professionals to monitor all their patients' adherence to the physical activity plan and to contact individual patients directly via the app.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care (standard of care) according to international and national cardiac rehabilitation guidelines.
Study: NCT06703255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX301+/Temozolomide
Description: Part I: It is planned to firstly explore a dose of 160 mg and enroll approximately 3-6 subjects to receive HX301 monotherapy until disease progression, intolerable toxicity, or other reasons for stopping treatment for up to 24 cycles of 28 days each. Safety evaluation was performed using the traditional 3 + 3 rule, and the DLT observation period was 28 days (C1D1 \~ C1D28). If 160 mg was not tolerated, it was reduced to 120 mg for exploration. Part II: Combination therapy phase: HX301 will be administered in combination with temozolomide approximately 4-6 weeks after completion of chemoradiotherapy. The TMZ dose will follow the first cycle: 150 mg/m 2 qd D1-D5, starting with the second cycle, and if the criteria for TMZ dose increase are met, TMZ will be administered as 200 mg/m 2 qd D1-D5 every 2 8 days for up to 12 cycles. Monotherapy maintain period: Following the end of temozolomide treatment, HX301 monotherapy will be continued for a maximum of 12 cycles of 28 days each.
Study: NCT06759649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM503
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM503
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM503
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM503
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COM503
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Intravenous infusion
Study: NCT06773403

Intervention type: DRUG
Group type: OTHER
Intervention: Upadacitinib
Description: All subject start on 15mg. At week 8 subjects may increase to 30mg if the investigators deems it necessary.
Study: NCT06771115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX3232 Dose A
Description: VTX3232 Dose A

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX3232 Dose A in combination with semaglutide
Description: VTX3232 Dose A in combination with semaglutide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo in combination with semaglutide
Description: Placebo in combination with semaglutide
Study: NCT06774300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS
Description: The intervention is the BASICS protocol outlined in the BASICS manual. It includes an online self-administered assessment and then delivery of a feedback session either in-person or over Zoom.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS
Description: The intervention is the BASICS protocol outlined in the BASICS manual. It includes an online self-administered assessment and then delivery of a feedback session either in-person or over Zoom.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online alcohol programming
Description: This is a control intervention that is used as the first-line sanction for students at the two universities. It is an online program, informed by BASICS content, but contains no facilitator and is self-directed.
Study: NCT06777485

Intervention type: PROCEDURE
Intervention: Procedure/Surgery treatment
Description: Routine surgical operations for patients with hepatocellular carcinoma, such as surgical resection, ablation，TACE，HAIC

Intervention type: DRUG
Intervention: Anti-Tumor Drugs
Description: Use of anti-tumor drugs, e.g., immunologic, targeted, and chemotherapy drugs
Study: NCT06776185

Intervention type: PROCEDURE
Intervention: Liver Surgery
Description: Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement. Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed

Intervention type: PROCEDURE
Intervention: Liver Surgery
Description: Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement. Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed

Intervention type: PROCEDURE
Intervention: Liver Surgery
Description: Minimally Invasive Liver Resection In both LLR and RALR, standardized preoperative planning with 3D imaging was utilized to assess tumor location, size, and proximity to vascular structures, enabling precise port placement. Typically, four to five trocar ports were inserted based on the tumor's location, with adjustments as needed
Study: NCT06776588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation combined with biopsy
Description: CT thin-layer scanning 3D reconstruction is used, and AI and fragment omics technology are used to evaluate the risk of malignant transformation of pulmonary nodules. Microwave ablation of pulmonary nodules is combined with intraoperative rapid pathology technology to determine the nature of punctured tissue and the degree of ablation, and to explore the optimal ablation time and ablation power.
Study: NCT06776016

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate
Description: Agent: The dietary supplement contains tributyrin, a pro-drug of butyrate. Method: Participants receive the supplement orally at a dose of 20 ml, 2-3 times daily, 12 weeks.
Study: NCT06776653

Intervention type: OTHER
Intervention: Tovertafel Pixie
Description: The Tovertafel Pixie® projector has a distracting effect, which can help divert the patient's attention while waiting for or undergoing treatment.
Study: NCT06509906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9466
Description: M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9466
Description: M9466 will be administered orally until progressive disease, unacceptable toxicity, death, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously once every 2 weeks (q2w) until progressive disease, unacceptable toxicity, death, or end of study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Folinic acid will be administered intravenously q2w as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU)
Description: Fluorouracil will be administered intravenously as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered intravenously, q2w until progressive disease, unacceptable toxicity, death, or end of study.
Study: NCT06775912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-05 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide
Study: NCT06777329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 days of dry immersion
Description: The volunteers in this arm will be immersed up to the neck for 10 days in a specially designed bath filled with tap water.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 days of Head Down Bed Rest
Description: The volunteers in this arm will spend 10 days in -6° head down bed rest.
Study: NCT06775704

Intervention type: DEVICE
Intervention: Hip resurfacing system
Description: Hip resurfacing with ROMAX system
Study: NCT06776848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation phase
Description: Start of the observation phase for all patients for a period of 6 months. Group B: continuation of the observation phase for a further 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation phase
Description: Start of the observation phase for all patients for a period of 6 months. Group B: continuation of the observation phase for a further 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Description: The daily dose of lithium will be increased until the target lithiaemia is reached, while monitoring tolerance and possible adverse effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Description: The daily dose of lithium will be increased until the target lithiaemia is reached, while monitoring tolerance and possible adverse effects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological monitoring
Description: The blood level of lithium will be monitored by regular blood tests~- every 4 days until a targeted blood level is obtained

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biological monitoring
Description: The blood level of lithium will be monitored by regular blood tests~- every 4 days until a targeted blood level is obtained
Study: NCT06775340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSS0343 Tabella
Description: RSS0343 tablets, oral;
Study: NCT06775379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azetukalner
Description: Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Study: NCT06776510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotinamide adenine dinucleotid/nicotinamide mononucleotide
Description: Drug: intravenous nicotinamide adenine dinucleotide (Coenzyme I for Injection) administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide adenine dinucleotide (100mg/d) for 1 week.~Drug: oral nicotinamide mononucleotide administration This study adopts a prospective, single arm, open design method. Twenty subjects were enrolled in the study and were treated with nicotinamide mononucleotide 450mg BID for 2 weeks.~The first stage is the main research stage (d0-w2), which is the core treatment period. The aim is to observe the safety and efficacy during treatment.~The second stage (w2-w8) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy after treatment.
Study: NCT06489262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Together (Juntos)
Description: Parent-adolescent dyads will log in to a secured website for six months. The intervention will be delivered primarily through smartphones and will include didactic content on healthy lifestyle behaviors (for parents/adolescents), family behavior change content for setting weekly goals and self-monitoring health behaviors (for parents/adolescents), and positive parenting content (for parents only), all of which were developed in accordance with participant feedback based on formative intervention development work. In addition, and to increase participant compliance/reduce attrition often observed in digital health interventions, human support (supportive accountability) will be provided. Specifically, each family will be assigned a coach who will use video conferencing software to engage in approximately weekly (during the first 3 months), and monthly (during the following 3 months) 20-30-minute sessions regarding the family's progress throughout the intervention period.
Study: NCT04939051

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophageal Biopsy
Description: Undergo esophageal biopsy, brushings and gastric aspirate

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophageal Biopsy
Description: Undergo esophageal biopsy, brushings and gastric aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD
Study: NCT05642611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, plasma, and serum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood, plasma, and serum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood, plasma, and serum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryocompression Therapy
Description: Undergo cryocompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Therapy
Description: Undergo continuous compression

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic Compression Therapy
Description: Undergo low cyclic compression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06019130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab during induction chemotherapy in all groups and during radiochemotherapy in patients with SD or PD after induction or metastases